Pillar guides on peptides.
English adaptations of pephealth's canonical Portuguese pillar guides. Each one covers a specific axis — somatotropic, GLP-1, tissue repair, evidence methodology — with the same editorial voice: clinical, referenced, neither prescriptive nor commercial.
Evidence hierarchy, without jargon
Meta-analysis, randomized trial, observational study, animal, in vitro. What each level says, what it doesn't say, and how to read 'studies show' without getting fooled.
Last reviewed: 2026-04-27 · Source (pt-BR): /guias/entenda-hierarquia-evidencia
GLP-1 overview — five molecules, the pivotal RCTs, and the Brazilian regulatory frame
Liraglutide, semaglutide, tirzepatide, retatrutide and what each phase 3 trial actually tested. Approvals, head-to-head data, and the regulatory layer that distinguishes industrialized from compounded products.
Last reviewed: 2026-04-27 · Source (pt-BR): /guias/glp-1-panorama
The growth hormone axis, without mystery
Hypothalamus → pituitary → liver → tissues. Why each pharmacological class enters at a different point in this pathway — and why that matters for an informed decision.
Last reviewed: 2026-04-27 · Source (pt-BR): /guias/eixo-gh
Tissue repair and performance — what exists, what doesn't, what is banned
Four peptide classes circulate as 'recovery' agents. Only two have published human RCTs, and none has multicenter phase 3 in musculoskeletal recovery. Map of the terrain in 2026.
Last reviewed: 2026-04-27 · Source (pt-BR): /guias/reparo-e-performance